title: Reduced levels of anti-MDA LDL antibodies in patients with carbohydrate metabolism disorders.
abstract: BACKGROUND
  Diabetic patients undergoing percutaneous coronary intervention (PCI) have a worse prognosis than non-diabetic patients. The anti-oxidized LDL antibodies (anti-LDLox ab) have recently been suggested to be protective against the development of diabetes. The aim of this study was to compare the levels of IgG and IgM anti-oxidized LDL antibodies with reference to the new diagnostic criteria for carbohydrate metabolism disorders after an oral glucose tolerance test (OGTT) in hospitalized patients scheduled to undergo percutaneous coronary intervention.
  
  
  METHODS
  We undertook a cross-sectional study of 110 patients undergoing PCI. The patients were classified as being normal (oral glucose test tolerance normal, OGTT-N), or having impaired glucose tolerance (IGT) or type 2 diabetes mellitus (T2DM) according to their glucose levels at baseline and after an OGTT.
  
  
  RESULTS
  An inverse slope was found in the levels of IgG anti-oxidized LDL antibodies between the OGTT-N patients (optical density (OD) = 0.109) and the patients with IGT (OD = 0.099) or T2DM (OD = 0.084) (p = 0.019). An inverse correlation was also detected between the levels of IgG anti-oxidized LDL antibodies and baseline glycemia (r = -0.23, p = 0.018).
  
  
  CONCLUSIONS
  Patients with coronary disease and carbohydrate metabolism disorders have much lower levels of IgG anti-oxidized LDL antibodies than normoglycemic patients.
authors.affiliation: CIBERDEM, Hospital Universitari Joan XXIII, IISPV, Tarragona, Spain. lourgarrido@gmail.com
authors.forename: Lourdes
authors.initials: L
authors.lastname: Garrido-Sánchez
authors.forename: J M
authors.initials: JM
authors.lastname: García-Pinilla
authors.forename: Manuel
authors.initials: M
authors.lastname: Jiménez-Navarro
authors.forename: Julia
authors.initials: J
authors.lastname: Fernández-Pastora
authors.forename: Juan H
authors.initials: JH
authors.lastname: Alonso-Briales
authors.forename: Jose M
authors.initials: JM
authors.lastname: Hernández-Garcia
authors.forename: Eduardo
authors.initials: E
authors.lastname: De-Teresa-Galván
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Tinahones
mesh_terms: D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000918:Antibody Specificity; D001324:Autoantigens / Q000276:immunology*; D001786:Blood Glucose / Q000032:analysis; D003327:Coronary Disease / Q000097:blood / Q000150:complications / Q000276:immunology; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000276:immunology*; D005260:Female; D018149:Glucose Intolerance / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000276:immunology*; D005951:Glucose Tolerance Test; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications / Q000276:immunology; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology*; D008077:Lipoproteins, LDL / Q000276:immunology*; D008297:Male; D008315:Malondialdehyde / Q000031:analogs & derivatives* / Q000276:immunology; D008875:Middle Aged; D010084:Oxidation-Reduction; D011379:Prognosis; D051437:Renal Insufficiency / Q000097:blood / Q000150:complications / Q000276:immunology
chemical_list: D001324:Autoantigens; D001786:Blood Glucose; D007074:Immunoglobulin G; D008077:Lipoproteins, LDL; C569869:malondialdehyde-low density lipoprotein, human; D008315:Malondialdehyde